ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Compared with BCR-ABL in CML and PML-RARα in APL, we have an extremely limited knowledge about the molecular functions of PMTs in normal and cancer development despite a preliminary indication of clinical efficacy of the KMT inhibitor against DOT1L in the phase I trial.